Opthea Competitors

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Opthea (NASDAQ:OPT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Analyst Recommendations

This is a summary of current ratings for BioCryst Pharmaceuticals and Opthea, as reported by MarketBeat.com.

BioCryst Pharmaceuticals presently has a consensus price target of $12.3333, indicating a potential upside of 19.16%. Opthea has a consensus price target of $36.00, indicating a potential upside of 260.72%. Given Opthea's stronger consensus rating and higher possible upside, analysts clearly believe Opthea is more favorable than BioCryst Pharmaceuticals.

Valuation and Earnings

This table compares BioCryst Pharmaceuticals and Opthea's gross revenue, earnings per share and valuation.

Opthea has lower revenue, but higher earnings than BioCryst Pharmaceuticals.

Profitability

This table compares BioCryst Pharmaceuticals and Opthea's net margins, return on equity and return on assets.

Insider & Institutional Ownership

72.0% of BioCryst Pharmaceuticals shares are owned by institutional investors. 4.3% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Opthea beats BioCryst Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Sangamo Therapeutics (NASDAQ:SGMO) and Opthea (NASDAQ:OPT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for Sangamo Therapeutics and Opthea, as provided by MarketBeat.com.

Sangamo Therapeutics currently has a consensus price target of $20.20, indicating a potential upside of 68.47%. Opthea has a consensus price target of $36.00, indicating a potential upside of 260.72%. Given Opthea's stronger consensus rating and higher possible upside, analysts plainly believe Opthea is more favorable than Sangamo Therapeutics.

Profitability

This table compares Sangamo Therapeutics and Opthea's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Sangamo Therapeutics and Opthea's gross revenue, earnings per share and valuation.

Opthea has lower revenue, but higher earnings than Sangamo Therapeutics.

Insider & Institutional Ownership

57.7% of Sangamo Therapeutics shares are owned by institutional investors. 1.8% of Sangamo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Opthea beats Sangamo Therapeutics on 6 of the 9 factors compared between the two stocks.

Opthea (NASDAQ:OPT) and Krystal Biotech (NASDAQ:KRYS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.

Institutional and Insider Ownership

73.1% of Krystal Biotech shares are held by institutional investors. 27.4% of Krystal Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Opthea and Krystal Biotech's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations for Opthea and Krystal Biotech, as provided by MarketBeat.com.

Opthea currently has a consensus target price of $36.00, suggesting a potential upside of 260.72%. Krystal Biotech has a consensus target price of $101.00, suggesting a potential upside of 31.73%. Given Opthea's higher possible upside, research analysts plainly believe Opthea is more favorable than Krystal Biotech.

Earnings and Valuation

This table compares Opthea and Krystal Biotech's revenue, earnings per share (EPS) and valuation.

Summary

Krystal Biotech beats Opthea on 4 of the 7 factors compared between the two stocks.

Opthea (NASDAQ:OPT) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and earnings.

Analyst Ratings

This is a breakdown of current ratings and target prices for Opthea and AlloVir, as reported by MarketBeat.com.

Opthea currently has a consensus target price of $36.00, suggesting a potential upside of 260.72%. AlloVir has a consensus target price of $48.75, suggesting a potential upside of 101.36%. Given Opthea's higher probable upside, analysts plainly believe Opthea is more favorable than AlloVir.

Earnings & Valuation

This table compares Opthea and AlloVir's gross revenue, earnings per share (EPS) and valuation.

Institutional & Insider Ownership

32.1% of AlloVir shares are owned by institutional investors. 1.0% of AlloVir shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Opthea and AlloVir's net margins, return on equity and return on assets.

Summary

AlloVir beats Opthea on 3 of the 5 factors compared between the two stocks.

Immunovant (NASDAQ:IMVT) and Opthea (NASDAQ:OPT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Institutional & Insider Ownership

40.2% of Immunovant shares are held by institutional investors. 0.2% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for Immunovant and Opthea, as reported by MarketBeat.com.

Immunovant presently has a consensus target price of $45.60, suggesting a potential upside of 184.82%. Opthea has a consensus target price of $36.00, suggesting a potential upside of 260.72%. Given Opthea's higher probable upside, analysts clearly believe Opthea is more favorable than Immunovant.

Profitability

This table compares Immunovant and Opthea's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Immunovant and Opthea's top-line revenue, earnings per share (EPS) and valuation.

Summary

Immunovant beats Opthea on 4 of the 7 factors compared between the two stocks.

Opthea (NASDAQ:OPT) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Profitability

This table compares Opthea and REGENXBIO's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations for Opthea and REGENXBIO, as reported by MarketBeat.

Opthea presently has a consensus target price of $36.00, indicating a potential upside of 260.72%. REGENXBIO has a consensus target price of $62.50, indicating a potential upside of 74.43%. Given Opthea's higher probable upside, equities research analysts plainly believe Opthea is more favorable than REGENXBIO.

Institutional and Insider Ownership

75.2% of REGENXBIO shares are held by institutional investors. 14.1% of REGENXBIO shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Opthea and REGENXBIO's top-line revenue, earnings per share and valuation.

Opthea has higher earnings, but lower revenue than REGENXBIO.

Summary

REGENXBIO beats Opthea on 5 of the 9 factors compared between the two stocks.